The Effect Of Fractional CO2 Laser Therapy On Cancer Survivors With Genitourinary Syndrome Of Menopause (GSM)

Inclusion Criteria: * Women who have had non-metastatic (M0, ≤Stage IIIA) cancer with any hormone receptor and her2 neu status who have completed cancer-related treatment\>=6 months prior to enrollment with no evidence of metastasis or currently active disease * Women currently on endocrine therapy, single agent Herceptin, or observation * Patient-reported dyspareunia and/or vaginal dryness with the severity of \>=4 on a scale from 0 (none) to 10 (most severe) that has been persistent for over \>= 4 weeks and/or the inability to be sexually active due to pain * Age 21 to 70 years * Subjects seeking treatment of GSM * Objective evidence of menopause: percentage of superficial vaginal epithelial cells of vaginal smear (MI) ≤ 5% and Vaginal fluid pH \> 4.5 (for women within the first 3 years post-menopause) * Normal Papanicolaou (PAP) test smear last performed as a standard of care * Negative urine analysis * Sexually active (having sexual intercourse at least once a month) or desire to maintain sexual activity * Informed consent process completed and subject signed a consent form. * Able and willing to comply with the treatment/follow-up schedule and requirements * Patient is willing to use non-hormonal contraception method during the course of the study. Exclusion Criteria: * Active genital infection. * Acute or (recurring) Urinary Tract Infection (UTI) or genital infection (e.g. Herpes or candida or (condyloma ) defined as \> 2 episodes in the recent year. * Hormonal repla…